These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 16406185)

  • 1. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66).
    Wu JJ; Chen HM; Ko WC; Wu HM; Tsai SH; Yan JJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):169-75. PubMed ID: 17913434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
    Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system.
    Lewis JS; Herrera M; Wickes B; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4015-21. PubMed ID: 17724160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interspecies spread of CTX-M-32 extended-spectrum beta-lactamase and the role of the insertion sequence IS1 in down-regulating bla CTX-M gene expression.
    Fernández A; Gil E; Cartelle M; Pérez A; Beceiro A; Mallo S; Tomás MM; Pérez-Llarena FJ; Villanueva R; Bou G
    J Antimicrob Chemother; 2007 May; 59(5):841-7. PubMed ID: 17332005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?
    Damjanova I; Tóth A; Pászti J; Hajbel-Vékony G; Jakab M; Berta J; Milch H; Füzi M
    J Antimicrob Chemother; 2008 Nov; 62(5):978-85. PubMed ID: 18667450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissemination of the CTX-M-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel.
    Navon-Venezia S; Chmelnitsky I; Leavitt A; Carmeli Y
    J Antimicrob Chemother; 2008 Aug; 62(2):289-95. PubMed ID: 18487232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
    Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
    J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extended-spectrum beta-lactamases-producing Stenotrophomonas maltophilia strains: CTX-M enzymes detection and virulence study].
    Lavigne JP; Gaillard JB; Bourg G; Tichit C; Lecaillon E; Sotto A
    Pathol Biol (Paris); 2008; 56(7-8):447-53. PubMed ID: 18848407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacter cloacae isolated from a district teaching hospital in Taiwan.
    Yu WL; Cheng KC; Chi CJ; Chen HE; Chuang YC; Wu LT
    Clin Microbiol Infect; 2006 Jun; 12(6):579-82. PubMed ID: 16700709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTX-M-1 extended-spectrum beta-lactamase-producing Proteus mirabilis in Greece.
    Karapavlidou P; Sofianou D; Manolis EN; Pournaras S; Tsakris A
    Microb Drug Resist; 2005; 11(4):351-4. PubMed ID: 16359194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of CTX-M-15, CTX-M-22, and SHV-2 extended-spectrum beta-lactamases (ESBLs) in Escherichia coli fecal-sample isolates from pig farms in China.
    Tian GB; Wang HN; Zou LK; Tang JN; Zhao YW; Ye MY; Tang JY; Zhang Y; Zhang AY; Yang X; Xu CW; Fu YJ
    Foodborne Pathog Dis; 2009 Apr; 6(3):297-304. PubMed ID: 19272004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002.
    Ho PL; Ho AY; Chow KH; Wong RC; Duan RS; Ho WL; Mak GC; Tsang KW; Yam WC; Yuen KY
    J Antimicrob Chemother; 2005 Jun; 55(6):840-5. PubMed ID: 15857942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.